Findings show that HUC-MSCs could reduce the OS levels of ovarian cancer cells and reduce the apoptosis of cells, which may be related to the ERK signaling pathway that regulates GSH metabolism, thereby providing a new theoretical basis for HUC-MSCs to treat POI. This evidence concerns the gene MAPK1 and ovarian carcinoma.